期刊論文1. | Schilling, Stephen H.(2011)。DNA as Patentable Subject Matter and a Narrow Framework for Addressing the Perceived Problems Caused by Gene Patents。Duke law journal,61(3),731-773。 |
2. | 李崇僖(20140100)。再探基因專利問題:美國經驗省思。月旦法學,224,304-307。 延伸查詢 |
3. | 陳文吟(20130400)。由Myriad案探討因應基因專利之合理措施。專利師,13,25-43。 延伸查詢 |
4. | 陳龍昇(20121200)。由美國Bilski v. Kappos案探討商業方法發明之專利適格性。臺北大學法學論叢,84,231-286。 延伸查詢 |
5. | Carbone, Julia(2010)。DNA Patents and Diagnostics: Not a Pretty Picture。Nature Biotechnology,28,784-791。 |
6. | Chandrasekharan, Subhashini(2014)。Do Recent U.S. Supreme Court Rulings on Patenting of Genes and Genetic Diagnostics Affect the Practice of Genetic Screening and Diagnosis in Prenatal and Reproductive Care?。Prenatal Diagnosis,34,921-926。 |
7. | Gold, E. Richard、Carbone, Julia(2010)。Myriad Genetics: In the Eye of the Policy Storm。Genetics in Medicine,12,S39-S70。 |
8. | Holman, Christopher M.(2012)。Will Gene Patents Derail the Next Generation of Genetic Technologies?: A Reassessment of the Evidence Suggests Not。UMCK Law Review,80(3),563-606。 |
9. | Ingram, Tup(2014)。Association for Molecular Pathology v. Myriad Genetics, Inc.: The Product of Nature Doctrine Revisited。Berkeley Technology Law Journal,29,385-417。 |
10. | Kesselheim, Aaron S.(2013)。Gene Patenting--The Supreme Court Finally Speaks。The New England Journal of Medicine,369,869-875。 |
11. | Kumar, Sapna(2014)。Life, Liberty, and the Pursuit of Genetic Information。Alabama Law Review,65,625-681。 |
12. | Kurts, Ann(2014)。Consequences of the US Supreme Court Decision on Gene Patenting。European Intellectual Property Review,35(11),629-636。 |
13. | Price, W. Nicholson(2012)。Unblocked Future: Why Gene Patents Won't Hinder Whole Genome Sequencing and Personalized Medicine。Cardozo Law Review,33,1601-1631。 |
14. | Rai, Arti(2014)。Diagnostic Patents at the Supreme Court。Marquette Intellectual Property Law Review,18,1-9。 |
15. | Russell, Tiana Leia(2012)。Unlocking the Genome: The Legal Case Against Genetic Diagnostic Patents。Marquette Intellectual Property Law Review,16,81-118。 |
16. | Stem, Richard(2013)。Association for Molecular Pathology v Myriad Genetics: Sieving the Gene Pool。European Intellectual Property Review,35(11),685-690。 |
17. | Torrance, Andrew W.、Kahl, Linda J.(2014)。Bringing Standards to Life: Synthetic Biology Standards and Intellectual Property。Santa Clara High Technology Law Journal,30,199-230。 |
18. | 楊智傑、王齊庭(20130700)。人體基因序列與診斷方法之專利適格性--以美國AMP v. USPTO & Myriad Genetics案為中心。生物產業科技管理叢刊,4(2),15-49。 延伸查詢 |
19. | Sherkow, Jacob S.(2014)。Preliminary Injunctions Post-Mayo and Myriad。Stanford Law Review Online,67,1-8。 |
20. | Sherkow, Jacob S.(2014)。The Natural Complexity of Patent Eligibility。Iowa Law Review,99,1137-1196。 |
21. | Sunder, Madhavi(2013)。Novartis v. Myriad: The Indian and US Supreme Courts on Patents and Public Health。European Intellectual Property Review,35,711-714。 |
22. | Allison, Malorye(2014)。Myriad Diversifies, Fights Rearguard Action on Patents。Nature Biotechnology,32。 |
23. | Andrews, Lori B.、Paradise, Jordan(2005)。Gene Patents: The Need for Bioethics Scrutiny and Legal Change。Yale Journal of Health Policy, Law, and Ethics,5,403-412。 |
24. | Bakshi, Ashish M.(2014)。Gene Patents at the Supreme Court: Association for Molecular Pathology v. Myriad Genetics。Journal of Law and the Biosciences,7,183-189。 |
25. | Bitton, Miriam(2004)。Patenting Abstractions。NC Journal of Law & Technology,15,153-231。 |
26. | Bogard, Olga(2010)。Comment, Patenting the Human Body: The Constitutionality of Gene Patents and Suggested Remedies for Reform。SMU Law Review,63,1319-1342。 |
27. | Chao, Bernard(2014)。The Infringement Continuum。Cardozo Law Review,35,1359-1413。 |
28. | Cook-Deegan, Robert(2013)。The Next Controversy in Genetic Testing: Clinical Data as Trade Secret?。European Journal of Human Genetics,21,585-589。 |
29. | Dreyfuss, Rochelle Cooper(2014)。Tailing Incentives: A Comment on Hemel and Ouellette's Beyond the Patents-Prizes Debate。Texas Law Review,92,131-144。 |
30. | Fowler, Cydney A.(2010)。Comment, Ending Genetic Monopolies: How the TRIPS Agreement's Failure to Exclude Gene Patents Thwarts Innovation and Hurts Consumers Worldwide。American University International Law Review,25,1073-1105。 |
31. | Georgek, Kevin J.(2014)。A Little Light on the Mayo: Justifying Reversal of the Federal Circuit's Association for Molecular Pathology Decision。Seton Hall Law Review,44,171-206。 |
32. | Ghosh, Samantak(2014)。Comment, The Taking of Human Biological Products。California Law Review,102,511-541。 |
33. | Harrison, Charlotte(2014)。Australian Court Upholds Myriad's Gene Patent。Nature Reviews Drug Discovery,13。 |
34. | Jain, Dipika(2014)。Gene-Patenting and Access to Healthcare: Achieving Precision。Houston Journal of International Law,36,101-146。 |
35. | Kane, Eileen M.(2004)。Splitting the Gene: DNA Patents and the Generic Code。Tennessee Law Review,71,707-767。 |
36. | La Belle, Megan M.(2014)。Against Settlement of (Some) Patent Cases。Vanderbilt Law Review,67,375-441。 |
37. | Lauer, Abigail(2011)。Comment, The Disparate Effects of Gene Patents on Different Categories of Scientific Research。Harvard Journal of Law & Technology,25,179-198。 |
38. | MacKenzie, Sean(2011)。Note, Recognizing the Building Blocks of Life as Products of Nature: Association for Molecular Pathology's Rightful Exclusion of Genetic Information from Patentable Subject Matter。Whittier Law Review,32,367-393。 |
39. | Park, Sandra(2014)。Gene Patents and the Public Interest: Litigation Association for Molecular Pathology v. Myriad Genetics and Lessons Moving Forward。North Carolina Journal of Law & Technology,15,519-536。 |